

Munehide Matsuhisa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9395481/publications.pdf>

Version: 2024-02-01

44
papers

631
citations

623734

14
h-index

610901

24
g-index

44
all docs

44
docs citations

44
times ranked

929
citing authors

#	ARTICLE	IF	CITATIONS
1	Basal insulin requirement in patients with type 1 diabetes depends on the age and body mass index. Journal of Diabetes Investigation, 2022, 13, 292-298.	2.4	4
2	Novel method utilizing bisulfite conversion with dual amplification of refractory mutation system polymerase chain reaction to detect circulating pancreatic β -cell cDNA. Journal of Diabetes Investigation, 2022, , .	2.4	1
3	Effectiveness of a Diabetes Oral Nursing Program Including a Modified Diabetes Oral Health Assessment Tool for Nurses (M-DiOHATA©) : A 12-Month Follow-Up Intervention Study. Journal of Medical Investigation, 2022, 69, 86-96.	0.5	1
4	Comparison of continuous subcutaneous insulin infusion treatment and multiple daily injection treatment on the progression of diabetic complications in Japanese patients with juvenile-onset type 1 diabetes mellitus. Journal of Diabetes Investigation, 2022, 13, 1528-1532.	2.4	1
5	Predictive Factors of the Adherence to Real-Time Continuous Glucose Monitoring Sensors: A Prospective Observational Study (PARCS STUDY). Journal of Diabetes Science and Technology, 2021, 15, 1084-1092.	2.2	14
6	Real-world data on the use of insulin glargine 300 U/mL in Japanese patients with type 1 diabetes: twelve-month results from a post-marketing surveillance study (X-STAR study). Expert Opinion on Pharmacotherapy, 2021, 22, 249-256.	1.8	2
7	High prevalence and clinical impact of dynapenia and sarcopenia in Japanese patients with type 1 and type 2 diabetes: Findings from the Impact of Diabetes Mellitus on Dynapenia study. Journal of Diabetes Investigation, 2021, 12, 1050-1059.	2.4	34
8	Risk of hypoglycemia in Japanese people with type 2 diabetes mellitus who initiated or switched to insulin glargine 300 U/mL: A subgroup analysis of 12-month post-marketing surveillance study (X-STAR) Tj ETQq0 02orgBT /Owlock 10		
9	Urinary adiponectin excretion is an early predictive marker of the decline of the renal function in patients with diabetes mellitus. Journal of Diabetes and Its Complications, 2021, 35, 107848.	2.3	5
10	Glycemic control status, diabetes management patterns, and clinical characteristics of adults with type 1 diabetes in Japan: Study of Adults' Glycemia in T1DM subanalysis. Diabetology International, 2021, 12, 460-473.	1.4	4
11	Plasma Heparin Cofactor II Activity Is Inversely Associated with Albuminuria and Its Annual Deterioration in Patients with Diabetes. Journal of Diabetes Investigation, 2021, , .	2.4	3
12	A low serum IGF-1 is correlated with sarcopenia in subjects with type 1 diabetes mellitus: Findings from a post-hoc analysis of the iDIAMOND study. Diabetes Research and Clinical Practice, 2021, 179, 108998.	2.8	8
13	Characterisation of Ppy-lineage cells clarifies the functional heterogeneity of pancreatic beta cells in mice. Diabetologia, 2021, 64, 2803-2816.	6.3	8
14	Skeletal FGFR1 signaling is necessary for regulation of serum phosphate level by FGF23 and normal life span. Biochemistry and Biophysics Reports, 2021, 27, 101107.	1.3	10
15	Japanese Society of Internal Medicine, 2021, 110, 420-426.	0.0	0
16	Circulating FGF23 is not associated with cardiac dysfunction, atherosclerosis, infection or inflammation in hemodialysis patients. Journal of Bone and Mineral Metabolism, 2020, 38, 70-77.	2.7	19
17	Development and Validation of the Continuous Subcutaneous Insulin Infusion-Related Quality-of-Life (CSII-QOL) Scale. Diabetes Technology and Therapeutics, 2020, 22, 216-221.	4.4	5
18	Development of fully automated and ultrasensitive assays for urinary adiponectin and their application as novel biomarkers for diabetic kidney disease. Scientific Reports, 2020, 10, 15869.	3.3	5

#	ARTICLE	IF	CITATIONS
19	Ethics and practical mitigations for ongoing clinical trials during the COVID-19 pandemic. <i>Diabetology International</i> , 2020, 11, 240-241.	1.4	0
20	Effectiveness and safety of insulin glargine 300 unit/mL in Japanese type 2 diabetes mellitus patients: a 12-month post-marketing surveillance study (X-STAR study). <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1771-1780.	1.8	1
21	Lower risk of severe hypoglycaemia with insulin glargine 300â€‰%U/<sc>mL</sc> versus glargine 100â€‰%U/<sc>mL</sc> in participants with type 1 diabetes: A <sc>metaâ€‰analysis</sc> of <sc>6â€‰month</sc> phase 3 clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1880-1885.	4.4	21
22	Nasal glucagon as a viable alternative for treating insulinâ€‰induced hypoglycaemia in Japanese patients with type 1 or type 2 diabetes: A phase 3 randomized crossover study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1167-1175.	4.4	15
23	In vitro and in vivo effects of insulin-producing cells generated by xeno-antigen free 3D culture with RCP piece. <i>Scientific Reports</i> , 2019, 9, 10759.	3.3	19
24	Clinical impact of sarcopenia and dynapenia on diabetes. <i>Diabetology International</i> , 2019, 10, 183-187.	1.4	23
25	Assessing the oral health of in-patients with diabetes using a clinical version of the Diabetes Oral Health Assessment ToolÂ© and its association with dental examinations. <i>Journal of Medical Investigation</i> , 2019, 66, 328-336.	0.5	4
26	Predictive factors of posttransplant glucose intolerance in Japanese patients with type 1 diabetes after pancreas transplantation. <i>Endocrine Journal</i> , 2019, 66, 1101-1112.	1.6	0
27	Association of accumulated advanced glycation endâ€‰products with a high prevalence of sarcopenia and dynapenia in patients with type 2 diabetes. <i>Journal of Diabetes Investigation</i> , 2019, 10, 1332-1340.	2.4	68
28	Activation of unliganded FGF receptor by extracellular phosphate potentiates proteolytic protection of FGF23 by its O-glycosylation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 11418-11427.	7.1	106
29	Circulating osteocalcin as a bone-derived hormone is inversely correlated with body fat in patients with type 1 diabetes. <i>PLoS ONE</i> , 2019, 14, e0216416.	2.5	10
30	Development of monoclonal mouse antibodies that specifically recognize pancreatic polypeptide. <i>Endocrine Journal</i> , 2019, 66, 459-468.	1.6	5
31	New risk factors of severe hypoglycemia. <i>Journal of Diabetes Investigation</i> , 2019, 10, 219-220.	2.4	6
32	The current status of treatmentâ€‰related severe hypoglycemia in Japanese patients with diabetes mellitus: A report from the committee on a survey of severe hypoglycemia in the Japan Diabetes Society. <i>Journal of Diabetes Investigation</i> , 2018, 9, 642-656.	2.4	30
33	The current status of treatment-related severe hypoglycemia in Japanese patients with diabetes mellitus: a report from the committee on a survey of severe hypoglycemia in the Japan Diabetes Society. <i>Diabetology International</i> , 2018, 9, 84-99.	1.4	14
34	Safety of the batteries and power units used in insulin pumps: A pilot crossâ€‰sectional study by the Association for the Study of Innovative Diabetes Treatment in Japan. <i>Journal of Diabetes Investigation</i> , 2018, 9, 903-907.	2.4	1
35	Predictors for the Treatment Effect of Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes Mellitus. <i>Advances in Therapy</i> , 2018, 35, 124-134.	2.9	16
36	Up-Titration Strategy After DPP-4 Inhibitor-Based Oral Therapy for Type 2 Diabetes: A Randomized Controlled Trial Shifting to a Single-Dose GLP-1 Enhancer Versus Adding a Variable Basal Insulin Algorithm. <i>Diabetes Therapy</i> , 2018, 9, 1959-1968.	2.5	2

#	ARTICLE	IF	CITATIONS
37	Advanced glycation end-products are a risk for muscle weakness in Japanese patients with type 1 diabetes. <i>Journal of Diabetes Investigation</i> , 2017, 8, 377-382.	2.4	51
38	Accuracy and Time Delay of Glucose Measurements of Continuous Glucose Monitoring and Bedside Artificial Pancreas During Hyperglycemic and Euglycemic Hyperinsulinemic Glucose Clamp Study. <i>Journal of Diabetes Science and Technology</i> , 2017, 11, 1096-1100.	2.2	9
39	A pilot study comparing the CGM-assessed glycaemic profiles of patients with type 1 diabetes on insulin degludec and insulin glargine. <i>Diabetology International</i> , 2017, 8, 112-115.	1.4	1
40	Sustained glycaemic control and less nocturnal hypoglycaemia with insulin glargine 300U/mL compared with glargine 100U/mL in Japanese adults with type 1 diabetes (EDITION JP 1 randomised) <i>Tj ETQq0 0 0 rgt /Overlock 10 Tf 5</i>	2.8	10
41	A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes. <i>Current Diabetes Reports</i> , 2016, 16, 83.	4.2	27
42	Regular insulin, rather than rapid-acting insulin, is a suitable choice for premeal bolus insulin in lean patients with type 2 diabetes mellitus. <i>Journal of Diabetes Investigation</i> , 2013, 4, 78-81.	2.4	2
43	Carbohydrate-to-Insulin Ratio Is Estimated from 300-400 Divided by Total Daily Insulin Dose in Type 1 Diabetes Patients Who Use the Insulin Pump. <i>Diabetes Technology and Therapeutics</i> , 2012, 14, 1077-1080.	4.4	9
44	Basal Insulin Requirement Is \approx 30% of the Total Daily Insulin Dose in Type 1 Diabetic Patients Who Use the Insulin Pump. <i>Diabetes Care</i> , 2011, 34, 1089-1090.	8.6	42